Back to top
more

Inspire Medical Systems (INSP)

(Delayed Data from NYSE)

$126.10 USD

126.10
907,460

+1.56 (1.25%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $126.01 -0.09 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (63 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Wall Street Analysts Predict a 39.04% Upside in Inspire (INSP): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 39% upside potential for Inspire (INSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

INSP Stock Gains Following Q1 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Inspire Medical's first-quarter 2025 performance reflects increased market penetration in existing centers and expansion into new territories and centers, along with strong domestic results.

Zacks Equity Research

Inspire Medical Systems (INSP) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 143.48% and 3.20%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Can Sustained Product Demand Drive HIMS Stock Before Q1 Earnings?

by Debanjana Dey

The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the first quarter of 2025.

Zacks Equity Research

BioSpin's Innovations to Support Bruker Shares, Macro Issues to Ail

by Zacks Equity Research

BRKR NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.

Zacks Equity Research

ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario

by Zacks Equity Research

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

Zacks Equity Research

Inspire (INSP) Down 6.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

RMD Stock Likely to Benefit From the New Brand Evolution Strategy

by Zacks Equity Research

In another major brand update, Resmed is likely to unify all the brands under one identity.

Zacks Equity Research

EPD Expansion Supports Abbot Stock, Macro Issues Prevail

by Zacks Equity Research

ABT's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Zacks Equity Research

ALGN Stock to Benefit From the Launch of Align X-ray Insights Solution

by Zacks Equity Research

Align Technologies unveils Align X-ray Insights, an AI-backed CADe solution.

Zacks Equity Research

QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel

by Zacks Equity Research

QIAGEN wins the FDA's clearance for the second QIAstat-Dx mini gastrointestinal panel.

Zacks Equity Research

Bruker Stock to Benefit From the Launch of X4 POSEIDON Benchtop XRM

by Zacks Equity Research

BRKR unveils X4 POSEIDON advanced XRM for 3D microscopy in industrial and scientific applications.

Zacks Equity Research

BSX Stock Set to Gain From the New Agreement to Acquire SoniVie Ltd.

by Zacks Equity Research

Boston Scientific inks a deal to acquire the remaining 90% stake in SoniVie Ltd.

Zacks Equity Research

Here's Why Inspire Medical Systems (INSP) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

How Much Upside is Left in Inspire (INSP)? Wall Street Analysts Think 25.88%

by Zacks Equity Research

The consensus price target hints at a 25.9% upside potential for Inspire (INSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

INSP Stock Declines Despite Q4 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the fourth quarter.

Zacks Equity Research

Inspire (INSP) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Inspire Medical Systems (INSP) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 55.41% and 0.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 5.26% and 3.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Countdown to Inspire (INSP) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Inspire (INSP), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Zacks Equity Research

Inspire Medical Systems (INSP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

by Zacks Equity Research

Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.

Zacks Equity Research

Premier Protein Momentum Likely to Fuel BellRing Brands' Q1 Earnings

by Zacks Equity Research

BRBR is expected to have gained from strong volume growth for Premier Protein in the first quarter of fiscal 2025.